OncoMatch/Clinical Trials/NCT07018570
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
Is NCT07018570 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for gastroesophageal junction (gej) adenocarcinoma.
Treatment: Pembrolizumab · Docetaxel · Oxaliplatin · Levofolinate · Fluorouracil (5-FU) — This study is to evaluate the effectiveness of treatment for esophagogastric junction carcinoma, total neoadjuvant therapy (TNT) including pembrolizumab and FLOT is conducted, aiming to choose between surgery or organ preservation treatment strategies.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Gastric Cancer
Esophageal Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-pd-1/pd-l1/pd-l2 antibody
Lab requirements
Blood counts
Neutrophil count ≥1,500/mm3; Hemoglobin ≥9.0 g/dL; Platelet counts ≥100,000/mm3
Kidney function
Serum creatinine ≤1.5 mg/dL
Liver function
Total bilirubin ≤1.5 mg/dL; AST (GOT) ≤100 IU/L; ALT (GPT) ≤100 IU/L
Neutrophil count ≥1,500/mm3; Hemoglobin ≥9.0 g/dL; Platelet counts ≥100,000/mm3; Total bilirubin ≤1.5 mg/dL; AST (GOT) ≤100 IU/L; ALT (GPT) ≤100 IU/L; Serum creatinine ≤1.5 mg/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07018570 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages